Intestinal Organoids

NCT ID: NCT05294107

Last Updated: 2024-08-27

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-09-06
• Study Completion Date: 2026-03-31

Brief Summary

Over the last decade, the use of mini-organ or organoids has been increasingly developed in fundamental research. Indeed, digestive organoids represent an essential advance compared to classical culture systems (epithelial cell lines, immortalized cells) since they preserve in culture the functional complexity present in vivo (architecture, different cell types). They also have the advantage of being able to be propagated indefinitely (unlike explants), minimizing the use of animal models and reducing the amount of tissue required. Finally, their growth and development depends on the origin of the sample (the organoid will develop differently if the cell source comes from a patient suffering from an inflammatory bowel disease, for example), thus generating models of human pathologies to better determine their physiopathology. The use of organoids in biomedical research has proven to be an indispensable tool for the understanding of cellular and molecular mechanisms involved in epithelial renewal and the screening of molecules and ingredients for applications in the health and agri-food sectors.

Detailed Description

The project aims to generate a biocollection of 3D intestinal models from digestive biopsies with associated health data and to characterize them before using them for the screening of potential therapeutic molecules.

Conditions

Digestive System Diseases; Inflammatory Bowel Disease, Ulcerative Colitis Type; Crohn Disease

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Group Crohn's disease

4 additional biopsies for 30 patients with Crohn's disease

Group Type: EXPERIMENTAL

additional biopsies

Intervention Type: PROCEDURE

After Verification of eligibility criteria, patient information and consent, digestive biopsies performed for the study are in addition to those performed for the patient's follow-up:

• 6 biopsies are taken on average in clinical routine
• 4 additional biopsies are necessary to obtain a sufficient number of amplifiable stem cells The samples will be sent within one hour to the Biological Resource Center of the University Hospital of Rennes at room temperature in a tube containing isotonic saline. (CRB).

Biopsies will be then prepared by isolating intestinal crypts and cultured on a 3D matrix gel (matrigel) with added growth factors reproducing the niche environment of intestinal stem cells, which favors the development of an intestinal epithelium. After intestinal differentiation, organoids will be used for research such as molecular screening, assessment of the effects of intestinal stress and healing.

Group ulcerative colitis

4 additional biopsies for 30 patients with ulcerative colitis

Group Type: EXPERIMENTAL

additional biopsies

Intervention Type: PROCEDURE

After Verification of eligibility criteria, patient information and consent, digestive biopsies performed for the study are in addition to those performed for the patient's follow-up:

• 6 biopsies are taken on average in clinical routine
• 4 additional biopsies are necessary to obtain a sufficient number of amplifiable stem cells The samples will be sent within one hour to the Biological Resource Center of the University Hospital of Rennes at room temperature in a tube containing isotonic saline. (CRB).

Biopsies will be then prepared by isolating intestinal crypts and cultured on a 3D matrix gel (matrigel) with added growth factors reproducing the niche environment of intestinal stem cells, which favors the development of an intestinal epithelium. After intestinal differentiation, organoids will be used for research such as molecular screening, assessment of the effects of intestinal stress and healing.

Group No MICI

4 additional biopsies for 30 patients out of Inflammatory Disease Chronic Bowel Disease

Group Type: ACTIVE_COMPARATOR

additional biopsies

Intervention Type: PROCEDURE

After Verification of eligibility criteria, patient information and consent, digestive biopsies performed for the study are in addition to those performed for the patient's follow-up:

• 6 biopsies are taken on average in clinical routine
• 4 additional biopsies are necessary to obtain a sufficient number of amplifiable stem cells The samples will be sent within one hour to the Biological Resource Center of the University Hospital of Rennes at room temperature in a tube containing isotonic saline. (CRB).

Biopsies will be then prepared by isolating intestinal crypts and cultured on a 3D matrix gel (matrigel) with added growth factors reproducing the niche environment of intestinal stem cells, which favors the development of an intestinal epithelium. After intestinal differentiation, organoids will be used for research such as molecular screening, assessment of the effects of intestinal stress and healing.

Interventions

additional biopsies

After Verification of eligibility criteria, patient information and consent, digestive biopsies performed for the study are in addition to those performed for the patient's follow-up:

• 6 biopsies are taken on average in clinical routine
• 4 additional biopsies are necessary to obtain a sufficient number of amplifiable stem cells The samples will be sent within one hour to the Biological Resource Center of the University Hospital of Rennes at room temperature in a tube containing isotonic saline. (CRB).

Biopsies will be then prepared by isolating intestinal crypts and cultured on a 3D matrix gel (matrigel) with added growth factors reproducing the niche environment of intestinal stem cells, which favors the development of an intestinal epithelium. After intestinal differentiation, organoids will be used for research such as molecular screening, assessment of the effects of intestinal stress and healing.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Subjects aged 18 to 75 years
• Subject undergoing endoscopy as part of the standard of care with the need to take digestive biopsy samples
• Subject having signed a free and informed consent in writing

Exclusion Criteria

• Subjects under legal protection (safeguard of justice, curatorship or guardianship) or deprived of liberty.
• Anticoagulant treatment and anti-platelet treatment (except for aspirin 75 mg)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Rennes University Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Guillaume BOUGUEN, Professor

Role: PRINCIPAL_INVESTIGATOR

Rennes University Hospital

Locations

CHU de RENNES-Service des Maladies de l'Appareil Digestif

Rennes, , France

Site Status: RECRUITING

Countries

France

Central Contacts

Guillaume BOUGUEN, Professor

Role: CONTACT

guillaume.bouguen@chu-rennes.fr

2 99 28 99 72 ext. +33

Facility Contacts

Guillaume BOUGUEN, Professor

Role: primary

Other Identifiers

35RC21_8862_BIOÏDES

Identifier Type: -

Identifier Source: org_study_id